节点文献

肺癌术后病人的肿瘤浸润淋巴细胞(TIL)和重组白细胞介素2(rIL-2)的全身应用

Systemic Administration of Autologous Tumor Infiltrating Lymphocytes (TIL) and Recombinant Interleukin-2 (rIL-2) to Patients with Lung Carcinoma after Resection of Primary Tumors

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 徐震逸张月桂李永庆巴德年邵杰孙凤林郑大勇李永堂陈云富

【Author】 Xu Zhenyi et al (Institute of Oncology)

【机构】 哈尔滨医科大学肿瘤研究所哈尔滨医科大学三院哈尔滨医科大学三院

【摘要】 <正> 我们已对肺癌浸润淋巴细胞的抗肿瘤活性,体外的增殖特征及与自身PBL的比较等进行了研究。实验表明,TIL在体外经rIL-2激活后可出现明显的抗肿瘤活性;在rIL-2存

【Abstract】 We have reported antitumor activity of lymphocytes infiltrating lung carcinomous tissue and thier in vitro expansion, comparison with autologous PBL. Here we report clinical application of TIL to patients with lung carcinoma who received surgical resection of thier primary lesions for the purpose of destroying free tumor cells in circulation and metastatic micro-loci, and preventing recurrence and metastases. Recombinant IL-2 (2×10~5u/day) were administrated ⅳ for 5 days. On second day, TIL were ⅳ transferred. Temporary low fever appeared in 2 cases among 3. No other toxic effect was observed. The results showed that immunotherapy with autologous TIL plus rIL-2 was safe and applicable.

【关键词】 TILrIL-2ImmunotherapyLung carcinoma
【Key words】 TILrIL-2ImmunotherapyLung carcinoma
  • 【文献出处】 哈尔滨医科大学学报 ,Journal of Harbin Medical University , 编辑部邮箱 ,1989年03期
  • 【被引频次】11
  • 【下载频次】23
节点文献中: 

本文链接的文献网络图示:

本文的引文网络